Key result
HCM screening in young athletes reduces mortality but incurs significant economic costs.
Why the study?
Sudden cardiac death in adolescent and young adult athletes due to hypertrophic cardiomyopathy is a serious concern with differing screening strategies and significant economic costs.
Screening for hypertrophic cardiomyopathy in young athletes reduces mortality but carries significant economic costs.
Sudden cardiac death (SCD) is an uncommon but devastating potential consequence of participation in competitive sport. It is seen in adolescent and young adult athletes. The most common cause of this, hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases and is manageable. Screening is undertaken for HCM, using differing strategies in Europe and North America. Screening and early diagnosis have reduced the mortality rate but has come at a significant economic cost. The evidence and relevant arguments for and against screening are presented together with management strategies as reflected by an illustrative case.
No takes yet. Share an insight, caveat, or question.
Fitzgerald et al. (2012) conducted a review in Hypertrophic cardiomyopathy. Screening for hypertrophic cardiomyopathy was evaluated. Screening and early diagnosis of hypertrophic cardiomyopathy in young athletes have reduced mortality rates but incur significant economic costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: